UNSPSC 51282140: Furbucillin

This classification denotes a penicillin antibiotic with the molecular formula C19H24N2O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 104NHK678E, chemically known as 6-((r)-2-hydroxy-4-methylvaleramido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 2-furoate (ester). but more generally known as furbucillin, which bears US NIH Compound Identifier 216269. European Medicines Agency schedules Furbucillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07836MIG.

UNSPSC 51282140 Furbucillin, a Commodity code, does not match the work actually being solicited under it in recent state and local opportunities. The recent opportunities tagged to this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives, medical and first aid supplies for emergency response, and generic pharmaceuticals through cooperative purchasing — none of which align with furbucillin as a pharmaceutical product category. The code shows a fundamental mismatch between its nominal scope and current procurement activity, limiting its utility for business development analysis.

The four most recent opportunities spanning January through June 2026 reflect either pharmaceutical supply coordination or emergency medical consumables procurement, but none target furbucillin specifically. Issuing bodies include Seminole County, Florida (IFB for naloxone and drug deactivation systems, due July 26, 2023); the Texas Health and Human Services Commission (RFI for direct-to-manufacturer prescription programs, due April 3, 2026); the City of Tampa (IFB for medical and first aid supplies, $700,000 estimated value, due March 13, 2026, with SLBE sheltered-market designation); and the Minnesota Multistate Cooperative Purchasing Alliance (RFP for generic pharmaceuticals and OTC products through authorized wholesalers, due March 26, 2026). Geographic activity spans Florida, Texas, Minnesota, and Oregon, but the underlying procurements address naloxone distribution, pharmacy benefit innovation, emergency medical supplies, and multi-source generic drugs rather than furbucillin procurement. Without recent solicitations explicitly requesting furbucillin, the code presents negligible opportunity value in the current market.